Home/Filings/4/0001209191-21-018041
4//SEC Filing

Holdbrook Mark J. 4

Accession 0001209191-21-018041

CIK 0001819790other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 8:14 PM ET

Size

5.5 KB

Accession

0001209191-21-018041

Insider Transaction Report

Form 4
Period: 2021-03-02
Holdbrook Mark J.
V.P., Clinical Affairs
Transactions
  • Award

    Stock Option (right to buy)

    2021-03-02+14,30014,300 total
    Exercise: $34.72Exp: 2031-03-02Common Stock (14,300 underlying)
Footnotes (1)
  • [F1]Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan. 25% of the option shares shall vest and become exercisable on March 2, 2022, and 1/48th of the option shares shall vest and become exercisable each month thereafter for a period of 3 years.

Issuer

Tarsus Pharmaceuticals, Inc.

CIK 0001819790

Entity typeother

Related Parties

1
  • filerCIK 0001827564

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 8:14 PM ET
Size
5.5 KB